Ganli Pharmaceutical (603087.SH) announced that Gan Li Pharmaceutical Shandong Co., Ltd., a wholly-owned subsidiary of the company, independently developed G...
Zhitong Finance App News, Ganli Pharmaceutical (603087.SH) announced that GZR18 tablets independently developed by Ganli Pharmaceutical Shandong Co., Ltd., a wholly-owned subsidiary of the company, are undergoing phase I clinical trials in China, and the first case was administered to the test subjects today.
According to reports, GZR18 tablets are an oral dosage form of GLP-1 analogue GZR18. GZR18 is a long-acting GLP-1 receptor agonist (GLP-1RA) being developed by Ganli Pharmaceutical. It has the characteristic of a long metabolic half-life in the body. The mechanism of action is that it can bind to and activate glucagon-like peptide-1 receptor (GLP-1R) to promote insulin release from pancreatic beta cells, inhibit pancreatic alpha cells to release glucagon, and at the same time delay gastric emptying and suppress appetite to comprehensively reduce blood sugar and improve obesity.